VPR Brands, LP.

VPR Brands, LP is a U.S.-based company focused on electronic cigarettes, personal vaporizers, and related nicotine and cannabis-adjacent products. Its business combines branded product design and distribution with patent ownership, trademark enforcement, intellectual property licensing, and private-label manufacturing programs.

28,7 %

−33,1 %

−36,3 %

0.57

0.27

— VPR Brands, LP.
%
Branded vaporizers45% Electronic cigarette and personal vaporizer devices sold under ELF and KRAVE.
E-liquids and consumables20% HELIUM-branded e-liquids and related consumable products used with vapor devices.
Specialty vapor devices15% HONEYSTICK products for oils, concentrates, and dry herbs.
CBD products10% GOLD LINE cannabidiol products and related wellness offerings.
Intellectual property and licensing10% Patent, trademark, and royalty-based licensing tied to the company’s IP portfolio.

VPR Brands sells to consumers through branded vapor and CBD products, and also monetizes its portfolio through...

  • Adult vapor product consumersprimary

    Buy ELF, KRAVE, HONEYSTICK, and HELIUM products for personal use.

  • Retail and wholesale channel partnersprimary

    Distributors, vape shops, and retailers that purchase finished goods for resale.

  • IP licenseessecondary

    Third parties that license patents or trademarks and pay royalties.

  • Private-label manufacturing customerssecondary

    Partners that source custom-branded vapor products and related items.

  • CBD product buyerssecondary

    Customers purchasing GOLD LINE cannabidiol products through retail or distribution channels.

VPR Brands is headquartered in the United States and its business is centered on U.S.-based product development,...

  • Headquartered in the United States
  • U.S. operations anchor product design, licensing, and distribution
  • No country-level revenue split was disclosed in the excerpts
  • Exposure is tied to U.S. consumer regulation and channel access
  • Licensing and private-label activity can extend beyond direct sales

The company’s stated direction is to broaden its product lineup with new vapor and related offerings while continuing...

01
Launch new product linesshort-term

New products are intended to offset weaker legacy demand and keep the brand portfolio relevant.

02
Monetize intellectual propertymedium-term

Patents and trademarks provide a licensing channel that can diversify revenue beyond product sales.

03
Grow private-label manufacturingmedium-term

Private-label programs can broaden distribution and create recurring commercial relationships.

VPR Brands faces demand risk from the highly competitive and regulated vapor industry, where consumer preferences and...

high

Declining product and royalty demand

The company disclosed lower product sales and royalty revenues tied to weaker customer sales and IP licensing activity.

Scope
Branded vapor products and licensing
Materiality
high
high

Capital raising and dilution risk

Management disclosed that inability to raise capital could curtail operations and that equity or convertible debt could dilute holders.

Scope
Liquidity and financing
Materiality
high
high

Regulatory risk in vapor and CBD markets

Electronic cigarettes, vaporizers, and CBD products are subject to changing federal, state, and local rules.

Scope
Product approvals, distribution, and marketing
Materiality
high
medium

Customer concentration and channel dependence

A small number of distributors, retailers, or licensees can materially affect sales and royalties.

Scope
Wholesale and licensing channels
Materiality
medium
Expected credit losses on accounts receivable
Allowance levels can change reported assets and bad debt expense
Deferred tax asset realizability
Valuation allowances can materially affect equity and tax expense
Revenue recognition for product sales and royalties
Quarterly revenue mix and comparability can vary
Lease accounting
Changes in lease assumptions affect assets, liabilities, and expense timing
Convertible notes and related-party obligations
May influence reported liabilities and equity dilution

: 29/04/2026